The CD1 family of proteins binds self and foreign glycolipids for presentation to CD1-restricted T cells. To identify previously uncharacterized active CD1 ligands, especially those of microbial origin, numerous glycolipids were synthesized and tested for their ability to stimulate mouse and human natural killer T (NKT) cells. They included analogs of the well known NKT cell agonist ␣-galactosyl ceramide (␣-GalCer), bacterial glycolipids, and variations of the self-glycolipid, sulfatide. Bacterial glycolipids, ␣-galacturonosyl-ceramides from Sphingomonas wittichii, although structurally similar to ␣-GalCer, have significant differences in the sugar head group as well as the ceramide portion. The Sphingomonas glycosphingolipids (GSLs) and sulfatide variants were shown to activate human NKT cells as measured by IL-4 and IFN-␥ secretion. Moreover, CD1d-dimer staining revealed human NKT cell reactivity toward these GSLs and to the sulfatides in a fashion comparable with ␣-GalCer. Because ␣-GalCer is a marine-sponge-derived ligand, our study here shows that bacterium-derived antigens are also able to stimulate mouse and human NKT cells.
C
D1 molecules are a family of highly conserved antigenpresenting proteins that are similar in function to classic MHC molecules (1) . Whereas classic MHC molecules present peptides, CD1 proteins bind and display a variety of lipids and glycolipids to T lymphocytes (2) . The five known isoforms are classified into two groups, group I (CD1a, CD1b, CD1c, and CD1e in humans) and group II (CD1d in humans and mice), based on similarities between nucleotide and amino acid sequences (3) .
A great diversity of lipids and glycolipids have been shown to bind specifically to each of the four isoforms. The first crystal structure of murine CD1d (mCD1d) revealed that it adopts a folded conformation closely related to major histocompatibility complex (MHC) class I proteins (4) . Also, it revealed that mCD1d could accommodate long lipid tails in two hydrophobic pockets, designated AЈ and FЈ, located in the binding groove. Two additional structures of hCD1b and hCD1a (5-7) confirmed this model by demonstrating that CD1, when loaded with antigenic glycolipids, binds the lipid portion in a hydrophobic groove while making the hydrophilic sugar moiety available to make contact with the T cell receptor.
Mammalian and mycobacterial lipids are known to be presented by human CD1a, CD1b, CD1c, and CD1d (1). ␣-Galactosyl ceramide (␣-GalCer), a lipid found in the marine sponge Agelas mauritianus (8) , has been the most extensively studied ligand for CD1d. ␣-GalCer, when bound to CD1d, stimulates rapid Th1 and Th2 cytokine production by V␣14i natural killer T (V␣14i NKT) cells in mice and the human homolog V␣24i NKT cells (9) (10) (11) (12) (13) (Fig. 1) . However, its physiological significance in mammals remains unclear because it is enigmatic why an ␣-galactosyl ceramide of marine origin is such a potent agonist. Other known ligands, which stimulate only relatively small populations of CD1d-restricted V␣14i NKT cells, include a bacterial phospholipid (PIM 4 ) and a tumor-derived ganglioside (GD3) (14, 15) . A phosphoethanolamine, found in human tumor extracts, was shown to be recognized by 24.8.A invariant NKT cell hybridomas (16) . The C-linked analog of ␣-GalCer (17) and ␣-GalCer analogs with different lipid chain lengths (18) have also been reported to have significant activities toward NKT cells.
As a part of our efforts to further understand the mechanism of CD1d-restricted T cell activation and the discovery of new glycolipid antigens, we have synthesized a number of glycolipids and tested them for NKT cell activation (Fig. 2) . These included glycolipids of bacterial origin (compounds 1, 2, 5, and 6), ␣-GalCer analogs modified on the galactose moiety and acyl group (compounds 10-18), and variations of sulfatide (compounds 7-9), the only known promiscuous ligand for CD1 (19) . The bacterial glycolipids included those isolated from the outer membrane of Sphingomonas wittichii (20) and glycolipids from Borrelia burgdorferi, the Lyme disease spirochete. CD1d-deficient (CD1d Ϫ/Ϫ ) mice were shown to have impaired host resistance to infection by B. burgdorferi, making its glycolipids attractive compounds for further study as possible natural CD1d antigens (21) . The structures of its two major glycolipids were recently elucidated as cholesteryl 6-O-acyl-␤-D-galactopyranoside, 5 (B. burgdorferi glycolipid 1, BbGL-I), and 1,2-di-O-acyl-3-O-␣-D-galactopyranosyl-sn-glycerol, 6 (BbGL-II) (22) . The Sphingomonas glycolipids, two previously uncharacterized ␣-linked glycosphingolipids (GSLs), 1 and 2 (GSL-1 and GSL-2, respectively), differ most significantly from ␣-GalCer in the carbohydrate moiety because they contain galactosyluronic acids as the polar head group (23) . However, they are more physiologically relevant as natural ligands for CD1d-mediated NKT cell activation because they originate from bacteria. Biological experiments further show that galactouronic sphingolipids stimulate IL-2 secretion in 1.2 (V␣14 V␤8.2 DN3A4) NKT cell hybridomas. An ␣-GalCer analog, 9, 3Љ-O-sulfo-galactosylceramide (3Љ-O-sulfo-GalCer), also caused significant IL-2 secretion, demonstrating that V␣14i NKT cell response is less sensitive to modification at the 3Љ-OH position of galactose. By contrast, any modification made at the 2Љ-OH position of galactose abolished all biological activity. Most other synthetic analogs, however, were active. In addition, we report the conservation of reactivity of human V␣24i NKT cells to GSL-1 and GSL-2 and sulfatides 7-9.
Materials and Methods
The synthesis of ␣-GalCer has been reported by this laboratory (24) . Compounds 16-18 were synthesized by the same procedure with slight modifications. Intermediates 19, 26, and 30 are known compounds (24) (25) (26) . Experimental details for 1, 2, 7, 20, 23, 27, and 31 are described. The synthesis of the remaining compounds, except 8 and 9, and their intermediates are reported separately in the supporting information, which is published on the PNAS web site. Sphingosine Intermediate Compound 20. As shown in Fig. 3 , compound 19 (3.31 g, 13.5 mmol) (25) was dissolved in 70 ml of dry tetrahydrofuran (THF). The solution was cooled to Ϫ40°C, and vinyl Grignard solution (31 ml of a 1 M solution in THF) was added via a dropping funnel over a period of 1 h. The temperature was kept between Ϫ20°C and Ϫ40°C. The reaction mixture was allowed to warm to room temperature and stirred for another hour. The (ii) HBTU, myristic acid or (S)-2-acetoxymyristic acid, n-morpholine, Ϸ92%, two steps. c, H 2, 20% Pd(OH)2, (ii) LiOH, H2O:THF:MeOH, 38%, two steps. d, 26, TMSOTf, 60%. e, (i) TFA, DCM, (ii) HBTU, myristic acid or (S)-2-acetoxymyristic acid, n-morpholine, Ϸ92%, two steps. f, (i) NaOMe, MeOH, (ii) Pd͞C, H 2, EtOH, 90%, two steps. g, 30, TMSOTf, 62%. h, (i) TFA, DCM, (ii) HBTU, nervonic acid, n-morpholine, 60%, two steps. i, (i) NaOMe, MeOH, quant; (ii) Bu 2SnO, MeOH; (iii) Me3N⅐SO3, THF, 95%. j and k, (i) LDA, TMSOOTMS, (ii) H ϩ , MeOH, 30%, two steps; then LiOH, H2O:MeOH, 81%; l, novozyme 435, CH2ACHOAc, 54% based on S isomer.
2 ml of anhydrous THF was added over freshly dried 4-Å molecular sieves and cooled to Ϫ50°C. Trimethylsilylmethyl trifluoromethanesulfonate (TMSOTf) (3.33 mg, 0.0198 mmol) was added, and the mixture was stirred at Ϫ50°C for 1 h. The mixture was allowed to warm to Ϫ20°C, and another 3.33 mg of TMSOTf was added. The mixture was then slowly allowed to warm to room temperature and stirred for 3 h. The solution was then diluted with EtOAc and filtered over Celite. The organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (MgSO 4 ), and concentrated. The residue was purified by column chromatography on silica gel (toluene:EtOAc 12:1) to give 128 mg (67.5%, 0.134 mmol) of 23. A general procedure for transformation of 23 to 24 can be found in the supporting information.
Compound 24 (36 mg, 0.03 mmol), dissolved in 6 ml of EtOAc, was added to 36 mg of 20% (wt) palladium hydroxide in 1 ml of EtOAc and saturated with hydrogen. The reaction vessel was purged with hydrogen, and the mixture was stirred at room temperature overnight. The reaction mixture was filtered, and the solvent was evaporated. The above hydrogenated compound was dissolved in 2 ml of THF, 1 ml of water, and 1 ml of methanol. LiOH (9 mg, 0.14 mmol) was added to the solution, and the reaction was stirred at room temperature for 4 h. We added 100 mg of Na 2 CO 3 , and the mixture was stirred for 30 min. The solvent was evaporated, and the remaining residue was purified on silica gel by column chromatography (CH 2 Cl 2 :MeOH 4:1) to give 7.8 mg of 1 (38%, 0.0114 mmol, two steps).
Sulfation of 32. After deprotection of compound 32 (14 mg, 0.017 mmol), Bu 2 SnO (6.5 mg, 0.0259 mmol) dissolved in 1 ml of MeOH was added. The mixture was refluxed under argon for 2 h. After evaporation of the solvent, Me 3 N⅐SO 3 (5 mg, 0.035 mmol) dissolved in 1 ml of THF was added, and the reaction was allowed to proceed at room temperature for 6 h. The solvent was then removed under reduced pressure, and the residue was dissolved in CHCl 3 ͞MeOH 1:1 (1 ml) and loaded onto an ion exchange column (Dowex, 50 ϫ 8 Na ϩ form). After elution with CHCl 3 ͞MeOH 1:1, the mixture was concentrated and purified by column chromatography (CH 2 Cl 2 :MeOH 5:1) to give 7 (14.4 mg, 95%).
Hybridoma Assay.
CD1d-reactive T cell hybridomas with an invariant V␣14i T cell antigen receptor ␣ chain have been described (27) . T cell hybridomas were stimulated with the indicated glycolipids that were added either to plates coated with soluble CD1d, or with CD1d-transfected A20 B lymphoma cells, according to published protocols (28) . As a measure of T cell activation, IL-2 release into the tissue culture medium was measured after a 16-h culture by an ELISA assay.
Generation of V␣24i Human NKT Cell Line. Human NKT cell lines, expressing the V␣24i T cell receptor as well as CD161, were generated as follows. Anti-CD161 mAbs, and anti-CD14 mAbs, each coupled to magnetic beads (Miltenyi Biotec, Auburn, CA), were used sequentially to isolate CD161 ϩ cells and CD14 ϩ cells from leukopaks. Immature dendritic cells were generated from the CD14 ϩ cells after a 2-day incubation in the presence of 300 units͞ml GM-CSF (R & D Systems) and 100 units͞ml IL-4 (R & D Systems). After irradiation with 2,000 rad, the immature dendritic cells were cocultured with syngeneic CD161 ϩ cells in the presence of 100 ng͞ml ␣-galactosylceramide and 10 units͞ml IL-2 (Invitrogen) for 10-14 days. After stimulating the CD161 ϩ cells a second time with ␣-galactosylceramide-pulsed, irradiated immature dendritic cells, NKT cell lines were shown flowcytometrically to express both CD161 ϩ and V␣24i T cell antigen receptor (99% purity).
In Vitro Cytokine Secretion Assay Using Human NKT Cell Lines. IFN-␥ and IL-4 secretion by the V␣24i human NKT cell line was determined by ELISA (BD Pharmingen) after culture for 16 h. For these assays, 1 ϫ 10 5 V␣24i human NKT cells were cocultured with 4 ϫ 10 5 irradiated, immature CD14 ϩ dendritic cells, in the presence of the glycolipid compounds at 10 g͞ml in a 96-well flat-bottom plate.
In Vitro CD1d-Dimer Assay Using a Human NKT Cell Line. We incubated 1 g of soluble divalent human CD1d-IgG 1 fusion protein (human CD1d-IgG 1 dimers, BD Pharmingen) overnight with 10 M each glycolipid at 32°C and at neutral pH according to the manufacturer's protocol. The glycolipid-loaded CD1d-IgG 1 dimers were incubated with human NKT cells at 4°C for 60 min, followed by incubation with PE-coupled anti-mouse IgG 1 mAb (A85-1). The cells were also surface-stained with a PerCPcoupled anti-CD3 mAb (BD Pharmingen).
Results and Discussion
Synthesis. We first synthesized the glycolipids of bacterial origin (1, 2, 5, and 6) of which the structures are similar to ␣-GalCer either at the sugar or lipid moiety and tested their CD1d-mediated NKT cell activation activities. Analogs 3 and 4 were prepared to probe the effect of the carboxyl group on the sugar and the ␣-hydroxyl group on the lipid. Compounds 7-9 contain a 3Љ-sulfate group with an ␣-or ␤-glycosidic linkage. Compounds 10-13 were prepared to probe the effect of the 2Љ modification of ␣-GalCer. Analogs of ␣-GalCer (16-18) with modification of the lipid moiety were also prepared to probe their interaction with CD1d and the subsequent effect on NKT cell activation. Murine 1.2 Hybridoma Assay. Mouse V␣14i NKT cells immortalized by cell fusion provide a convenient method for assaying the ability of the synthetic glycolipids to activate T cells. As shown in Fig. 5A, 3Љ -O-sulfo-␣-GalCer, 9, stimulated significant IL-2 release from the hybridomas when used at 10 g͞ml. Doseresponse curves indicated, however, that this compound was somewhat less active than ␣GalCer (data not shown) in this model. By contrast, every modification of the 2Љ-OH position of the galactose (compounds 10-13) that was tested abolished all biological activity. These data indicate that the V␣14i NKT cell response to glycolipids apparently is more sensitive to modifications of the 2 position than the 3 position. The B. burgdorferi glycolipids (5 and 6) and compounds 14 and 15 were moderately active in the 1.2 hybridoma assay. However, IL-2 secretion could only be detected when large quantities of the glycolipids were used to stimulate the hybridoma cells (unpublished data).
CD1d-coated plates were used to assay response of the hybridomas to the Sphingomonas glycolipids (Fig. 5B). A substantial level of IL-2 secretion can be observed for all compounds. The structure of the sugar head group significantly affected the activation of the hybridomas. ␣-GalCer and the galactose analog, 3, consistently solicited greater IL-2 secretion when compared with the galacturonic acid derivatives. Also affecting activity was the (S)-2-hydroxy of the fatty amide tail. A fully saturated tail was more greatly favored, suggesting that the ␣-hydroxyl group is not optimal. This finding is in agreement with previous structure-activity studies (8) of the marine sponge glycolipid, ␣-GalCer, which showed the same result. In fact, the (S)-2-hydroxy appeared to have a greater affect on activity as compound 4, a galactose analog, that was less able to activate IL-2 secretion when compared with 1, the galacturonic acid compound without the ␣-hydroxyl fatty amide. Although 3 and 4 have not been reported as natural products, both could be precursors to compounds 1 and 2. ␣-GalCer but twice that induced by the other glycolipids. Surprisingly, ␤-linked sulfatides 7 and 8 were observed to elicit both IFN-␥ and IL-4 production. In fact, the level of cytokine secretion was comparable to the GSLs. Other ␣-GalCer analogs with an acetyl side chain or a shortened backbone were also tested, and some activity was also observed (data not shown).
Human NKT Cell Lines Bind to Glycolipids in the Context of CD1d.
Although glycolipids stimulate the NKT cell line, we cannot invariably conclude that the glycolipids are presented by CD1d molecules and are capable of triggering the V␣24i T cell receptor expressed by the NKT cells. Therefore, to confirm the glycolipid antigen reactivity to the V␣24i T cell receptor at the single-cell level, we stained a human NKT cell line with human CD1d dimers loaded with different glycolipids, using unloaded CD1d dimers as a negative control. Each glycolipid-loaded dimer nearly universally stained the human NKT cells, whereas the unloaded dimer did not stain these cells (Fig. 6B) .
Computer Modeling of GSL Complexed to mCD1d. To further understand the interaction of bacterial glycolipid 1 with CD1d, a model generated by AUTODOCK 3.0 (29) of GSL 1 complexed with the crystal structure of mCD1d was shown in Fig. 7 (4) . In this model, the fatty acyl chain extends into the FЈ pocket, and the sphingosine chain extends toward the AЈ pocket. This allowed the polar head group to be oriented such that it was exposed for recognition by a T cell antigen receptor. Numerous favorable contacts could be observed between mCD1d and the GSL. Among them, possible hydrogen bonding included interactions between the carboxylate of the sugar and the backbone carbonyl of Asp-80, and the amide nitrogen of the fatty-acid tail with the Asp-80 side chain.
Studies (30) have shown mCD1d to be somewhat accommodating in terms of lipid tail length on NKT cell reactivity. However, changes in the lipid length, composition, or addition of an ␣-hydroxyl group on the fatty acid could cause a slight shift in orientation of the sugar, thereby affecting how the CD1d͞ glycolipid complex is recognized by the T cell receptor. This could also be true of the substitution of galacturonic acid for galactose. The perturbation caused by having the 6Љ-OH oxidized to a carboxylic acid caused only moderate changes in NKT cell reactivity.
Conclusion
In summary, a number of glycolipids were synthesized and tested for their ability to activate NKT cells. Of particular interest were sulfatides 7-9 and the Sphingomonas GSLs, which showed considerable activity as measured by cytokine production. Although none of the compounds were as potent as ␣-GalCer, specific responses were obtained to an ␣-GalCer analog, 3Љ-Osulfo-␣-GalCer, 9, but not to any of the four compounds having a modification of the equatorial 2Љ-OH of the galactose. Furthermore, glycolipid͞CD1d dimer staining of human V␣24i NKT cells showed reaction toward the Sphingomonas GSLs (GSL-1 and GSL-2) and sulfatides 7-9 when compared with ␣-GalCer. We were also able to demonstrate responses to the Sphingomonas compounds in vivo, and mice deficient for NKT cells have a reduced ability to clear bacteria from the liver (Y.K., D.W., G. Kim, G.-W.X., M.A.P., M.T., K. Kawahara, C.-H.W., and M.K., unpublished work).
Bacterial ␣-galacturonosyl ceramides have been shown to elicit activity from both mouse and human NKT cell lines. As measured by cytokine release and CD1d dimer͞glycolipid staining of a human NKT cell line, 3Љ-O-sulfo-GalCer, 9, had comparable potency to the exceptional agonist ␣-GalCer, showing that some flexibility can be accommodated at the 3Љ-OH position of galactose. Any modification at the 2Љ-OH position almost completely abolished activity. The Sphingomonas GSLs are reactive to the same population of human V␣24i NKT cells as ␣-GalCer, showing that bacterium-derived antigens are also able to activate NKT cells.
